ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

mylan pharmaceuticals limited - gefitinib - karsinom, ikke-småcellet lunge - antineoplastic agents, protein kinase inhibitors - gefitinib mylan er indisert som monoterapi for behandling av voksne pasienter med lokalt avansert eller metastatisk ikke‑liten celle lunge kreft (nsclc) med aktiverende mutasjoner i egfr‑tk.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

astrazeneca ab - gefitinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - iressa er indisert for behandling av voksne pasienter med lokalt avansert eller metastatisk ikke-liten celle lunge kreft med aktiverende mutasjoner av epidermal vekst-faktor-reseptor tyrosin kinase.

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

janssen-cilag as - itrakonazol - kapsel, hard - 100 mg

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

bayer ag - riociguat - hypertensjon, pulmonal - antihypertensive midler for pulmonal arteriell hypertensjon - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. effekten har vært vist i en pah befolkningen, herunder aetiologies av idiopatisk eller heritable pah eller pah assosiert med bindevev sykdom. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

roche registration gmbh - vemurafenib - melanom - antineoplastiske midler - vemurafenib er indisert i monoterapi for behandling av voksne pasienter med braf-v600-mutasjons-positiv, uoppløselig eller metastatisk melanom.

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

orifarm healthcare a/s - fenobarbital - tablett - 50 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

ratiopharm gmbh - ranitidinhydroklorid - tablett, filmdrasjert - 150 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

ratiopharm gmbh - ranitidinhydroklorid - tablett, filmdrasjert - 300 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sandoz - københavn - rifampicin / isoniazid - tablett, filmdrasjert - 150 mg / 75 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sandoz - københavn - rifampicin / isoniazid / pyrazinamid / etambutolhydroklorid - tablett, filmdrasjert - 150 mg / 75 mg / 400 mg / 275 mg